Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children

Neurology. 2004 Jan 27;62(2):194-200. doi: 10.1212/wnl.62.2.194.

Abstract

Background: Increased anticardiolipin antibody (ACLA) immunoglobulin (Ig) G titers are commonly found in children with arterial ischemic stroke (AIS) or TIA (AIS/TIA). The associated risk of recurrent thromboembolism is unknown.

Objective: To determine the risk of recurrent thromboembolism associated with persistently increased ACLA titers of the IgG isotype in children with AIS/TIA.

Methods: The authors studied a cohort of children surviving first AIS/TIA tested by standardized ELISA for beta2-glycoprotein I-dependent ACLA of the IgG isotype. Children with ACLA titers >15 IgG phospholipid (GPL) units (per manufacturer's cutoff point) on more than two occasions > or =6 weeks apart were classified as ACLA-positive (ACLA+) and compared with ACLA-negative (ACLA-) children with respect to recurrent thromboembolic events (AIS/TIA, sinovenous thrombosis, and extracerebral thromboembolism).

Results: The authors recruited 34 ACLA+ children and 151 ACLA- children. Most ACLA+ children (30/34; 88%) had ACLA titers < or =40 GPL units. During the follow-up period (median duration, 2.8 years for ACLA+ children and 3.0 years for ACLA- children), AIS/TIA recurred in 26% of ACLA+ children and in 38% of ACLA- children; none developed sinovenous thrombosis or extracerebral thromboembolism. Based on survival analysis, this difference was nonsignificant (p = 0.54). Using binary partition evaluation, no titer criteria for ACLA positivity (range, 0 to 60 GPL units) predicted recurrent AIS/TIA.

Conclusion: In children surviving arterial ischemic stroke/TIA, increased anticardiolipin antibody immunoglobulin G titers do not predict recurrent thromboembolism.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Anticardiolipin / blood*
  • Antiphospholipid Syndrome / blood
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / immunology
  • Brain Ischemia / blood
  • Brain Ischemia / epidemiology
  • Brain Ischemia / etiology*
  • Brain Ischemia / immunology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Comorbidity
  • Confounding Factors, Epidemiologic
  • Disease-Free Survival
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G / blood*
  • Ischemic Attack, Transient / blood
  • Ischemic Attack, Transient / epidemiology
  • Ischemic Attack, Transient / etiology*
  • Ischemic Attack, Transient / immunology
  • Life Tables
  • London / epidemiology
  • Male
  • Ontario / epidemiology
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prospective Studies
  • Recurrence
  • Risk
  • Survival Analysis
  • Thrombophilia / blood
  • Thrombophilia / drug therapy
  • Thrombophilia / etiology*
  • Thrombophilia / immunology

Substances

  • Antibodies, Anticardiolipin
  • Fibrinolytic Agents
  • Immunoglobulin G
  • Platelet Aggregation Inhibitors